FDA Brief

Warning letters Drugs

FDA warning letter to

CDL Services, Inc. DBA Technichem

High riskIssued Nov 24, 2025Posted Dec 9, 2025Center for Drug Evaluation and Research (CDER)

FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

What happened

FDA inspected CDL Services, Inc. DBA Technichem at 3080 E La Jolla Street, Anaheim, CA, from April 7 to 28, 2025. Investigators found the firm had not tested finished drug products in over a year and that finished product testing data shown during the inspection was simulated. FDA also found no identity testing of incoming components such as glycerin, ethanol and chloroxylenol, and that a gas chromatograph and its computer system were not made available to the inspection team.

What FDA found

  1. The company released batches of drug product to the market without laboratory testing to confirm the identity and strength of the active ingredients.

    21 CFR 211.165(a)
  2. The company did not test each incoming lot of each component for identity and did not periodically verify its suppliers' certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company did not test high-risk components for hazardous impurities: ethanol for methanol, and glycerin and propylene glycol for diethylene glycol or ethylene glycol, and did not show that the water it uses is suitable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The quality control unit lacked written procedures and oversight, including for complaints, supplier qualification, change control, batch records and access controls on computer systems.

    21 CFR 211.22(a) and 211.22(d)
  5. Drug products carry expiration dates that are not supported by stability testing.

    21 CFR 211.137(a)
  6. The gas chromatograph and its associated computer system were not available to FDA investigators, limiting FDA's access to records.

    Section 501(j) of the FD&C Act

What FDA wants

Respond in writing within 15 working days describing what has been done to correct the violations and prevent recurrence, or give reasons for delay and a completion schedule. The letter also requires diethylene glycol/ethylene glycol and methanol test results from retained samples within 30 calendar days, and recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands and retailers that buy OTC hand sanitizer or soap from this contract manufacturer
  • companies using glycerin, ethanol or propylene glycol as drug ingredients
  • distributors and private-label sellers of OTC topical drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk